NCT05092373View on ClinicalTrials.gov

Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax

PHASE1RecruitingINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

April 29, 2022

Primary Completion Date

September 1, 2026

Study Completion Date

September 1, 2026

Conditions
Advanced Breast CarcinomaAdvanced Endometrial CarcinomaAdvanced Fallopian Tube CarcinomaAdvanced Hepatocellular CarcinomaAdvanced Malignant Abdominal NeoplasmAdvanced Malignant Female Reproductive System NeoplasmAdvanced Malignant Thoracic NeoplasmAdvanced Ovarian CarcinomaAdvanced Primary Peritoneal CarcinomaAdvanced Renal Cell CarcinomaAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Malignant Abdominal NeoplasmMalignant Solid NeoplasmMetastatic Breast CarcinomaMetastatic Endometrial CarcinomaMetastatic Fallopian Tube CarcinomaMetastatic Hepatocellular CarcinomaMetastatic Malignant Abdominal NeoplasmMetastatic Malignant Female Reproductive System NeoplasmMetastatic Malignant Thoracic NeoplasmMetastatic Ovarian CarcinomaMetastatic Primary Peritoneal CarcinomaMetastatic Renal Cell CarcinomaPrognostic Stage III Breast Cancer AJCC v8Prognostic Stage IIIA Breast Cancer AJCC v8Prognostic Stage IIIB Breast Cancer AJCC v8Prognostic Stage IIIC Breast Cancer AJCC v8Prognostic Stage IV Breast Cancer AJCC v8Stage III Fallopian Tube Cancer AJCC v8Stage III Hepatocellular Carcinoma AJCC v8Stage III Ovarian Cancer AJCC v8Stage III Primary Peritoneal Cancer AJCC v8Stage III Renal Cell Cancer AJCC v8Stage III Uterine Corpus Cancer AJCC v8Stage IIIA Fallopian Tube Cancer AJCC v8Stage IIIA Hepatocellular Carcinoma AJCC v8Stage IIIA Ovarian Cancer AJCC v8Stage IIIA Primary Peritoneal Cancer AJCC v8Stage IIIA Uterine Corpus Cancer AJCC v8Stage IIIA1 Fallopian Tube Cancer AJCC v8Stage IIIA1 Ovarian Cancer AJCC v8Stage IIIA2 Fallopian Tube Cancer AJCC v8Stage IIIA2 Ovarian Cancer AJCC v8Stage IIIB Fallopian Tube Cancer AJCC v8Stage IIIB Hepatocellular Carcinoma AJCC v8Stage IIIB Ovarian Cancer AJCC v8Stage IIIB Primary Peritoneal Cancer AJCC v8Stage IIIB Uterine Corpus Cancer AJCC v8Stage IIIC Fallopian Tube Cancer AJCC v8Stage IIIC Ovarian Cancer AJCC v8Stage IIIC Primary Peritoneal Cancer AJCC v8Stage IIIC Uterine Corpus Cancer AJCC v8Stage IIIC1 Uterine Corpus Cancer AJCC v8Stage IIIC2 Uterine Corpus Cancer AJCC v8Stage IV Fallopian Tube Cancer AJCC v8Stage IV Hepatocellular Carcinoma AJCC v8Stage IV Ovarian Cancer AJCC v8Stage IV Primary Peritoneal Cancer AJCC v8Stage IV Renal Cell Cancer AJCC v8Stage IV Uterine Corpus Cancer AJCC v8Stage IVA Fallopian Tube Cancer AJCC v8Stage IVA Hepatocellular Carcinoma AJCC v8Stage IVA Ovarian Cancer AJCC v8Stage IVA Primary Peritoneal Cancer AJCC v8Stage IVA Uterine Corpus Cancer AJCC v8Stage IVB Fallopian Tube Cancer AJCC v8Stage IVB Hepatocellular Carcinoma AJCC v8Stage IVB Ovarian Cancer AJCC v8Stage IVB Primary Peritoneal Cancer AJCC v8Stage IVB Uterine Corpus Cancer AJCC v8
Interventions
BIOLOGICAL

Atezolizumab

Given IV

DRUG

Cabozantinib S-malate

Given PO

DRUG

Nab-paclitaxel

Given IV

PROCEDURE

Tumor Treating Fields Therapy

Receive TTF

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER